Glioblastoma multiform (GMB) is the most common central nervous system cancer. With an average survival of about 14 months, it is also one of the most aggressive central nervous system malignancies. A paper released in the latest publication of Nature, titled Genetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma, provides valuable insight on ways to bypass the blood-brain barrier, which often limits the success of systemic therapies. Researchers from Weill Cornell Medical College developed a method to modify cells in the brain using virus gene transfer vectors. Their studies showed reduction in tumor volume and increased survival.
Posted on: Mon, 15 Dec 2014 17:05:40 +0000